Study of HS-20093 combinations for extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This early-phase trial tests a new combination of drugs (HS-20093 plus other treatments) for people with extensive-stage small cell lung cancer whose cancer has not grown after their first round of treatment. The goal is to see if this new approach can keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have extensive-stage small cell lung cancer
- You finished first-line treatment (platinum chemo + immunotherapy) and the cancer didn't grow
- You are fully active or have only mild limitations (ECOG 0-1)
- You have no untreated or active brain metastases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three treatments for extensive-stage small cell lung cancer that has worsened after initial chemotherapy: an experimental pill, focused radiation (SBRT), and an immunotherapy drug. The goal is to see if this triple therapy can help the immune system fight the cancer more effectively.
This study tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy followed by targeted chest radiation as the first treatment for extensive-stage small cell lung cancer. The goal is to see if adding radiation after chemo-immunotherapy works better than standard treatment alone.
This study tests a new drug called HS-20093 for people with limited-stage small cell lung cancer that has not spread and has already been treated with chemotherapy and radiation. The goal is to see if this drug helps keep the cancer from coming back, compared to just watching and waiting.
This trial is testing a new approach for extensive-stage small cell lung cancer (SCLC) that has not been treated before. It combines a high-dose chemotherapy regimen with a drug called adebrelimab (an immunotherapy) and a stem cell transplant to help your body recover. The goal is to see if this powerful combination can work better than standard treatment.
This trial tests a combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus chemotherapy for people with extensive-stage small cell lung cancer. It's for those who either haven't been treated before or have had only one prior treatment that included a PD-1/PD-L1 drug and it worked for a while.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.